Advances in nanomedicines for diagnosis of central nervous system disorders

Xun Zhang,Jie Zhou,Zhongwei Gu,Hu Zhang,Qiyong Gong,Kui Luo

DOI: https://doi.org/10.1016/j.biomaterials.2020.120492

IF: 14

2021-02-01

Biomaterials

Abstract:<p>In spite of a great improvement in medical health services and an increase in lifespan, we have witnessed a skyrocket increase in the incidence of central nervous system (CNS) disorders including brain tumors, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease), ischemic stroke, and epilepsy, which have seriously undermined the quality of life and substantially increased economic and societal burdens. Development of diagnostic methods for CNS disorders is still in the early stage and the clinical outcomes suggest these methods are not ready for the challenges associated with diagnosis of CNS disorders, such as early detection, specific binding, sharp contrast, and continuous monitoring of therapeutic interventions. Another challenge is to overcome various barrier structures during delivery of diagnostic agents, especially the blood-brain barrier (BBB). Fortunately, utilization of nanomaterials has been pursued as a potential and promising strategy to address these challenges. This review will discuss anatomical and functional structures of BBB and transport mechanisms of nanomaterials across the BBB, and special emphases will be placed on the state-of-the-art advances in the development of nanomedicines from a variety of nanomaterials for diagnosis of CNS disorders. Meanwhile, current challenges and future perspectives in this field are also highlighted.</p>

engineering, biomedical,materials science, biomaterials

What problem does this paper attempt to address?

The paper attempts to address the diagnostic challenges of central nervous system (CNS) diseases. Specifically, it focuses on the significant increase in the incidence of CNS diseases such as brain tumors, neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease), ischemic stroke, and epilepsy. These diseases severely impair people's quality of life and bring enormous economic and social burdens. However, current diagnostic methods for these diseases are still in the early stages, and clinical results indicate that these methods are unable to meet the challenges associated with CNS disease diagnosis, such as early detection, specific binding, high-contrast imaging, and continuous monitoring of therapeutic interventions. Additionally, diagnostic agents need to overcome various structural barriers during delivery, particularly the blood-brain barrier (BBB), which is also a major challenge.

To address these challenges, the paper explores the application of nanomaterials as a potential and promising strategy. It discusses the anatomical and functional structure of the BBB and the transport mechanisms of nanomaterials across the BBB, highlighting the latest advancements in nanomedicines made from various nanomaterials for CNS disease diagnosis. The paper also points out the current bottlenecks and future research directions.